Payment overview · 2025
General Payments
$476.24
24 reported records · 14 companies
Healthcare provider profile · identity verified
Bipin G Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · AMSTERDAM, NY · NPI 1285653931
Verified facts
What the public records show
CMS Open Payments records show Bipin G Patel, M.D. received $476.24 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.53 | 29.1% | 6 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $70.50 | 14.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.05 | 13.7% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $26.13 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.58 | 5.2% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $21.48 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.12 | 4.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.52 | 4.3% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.84 | 3.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $15.33 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.05 | 3.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.04 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.49 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.74 | 20 |
| Education | $70.50 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.73 | 5 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $70.50 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.52 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.03 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 179 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
179 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 84 |
| Omeprazole | Omeprazole | 299 | 55 |
| Furosemide | Furosemide | 273 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 43 |
| Gabapentin | Gabapentin | 208 | 39 |
| Losartan Potassium | Losartan Potassium | 189 | 35 |
| Jardiance | Empagliflozin | 179 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 36 |
| Calcitriol | Calcitriol | 158 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 15 |
| Celecoxib | Celecoxib | 97 | 18 |
| Meloxicam | Meloxicam | 97 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 19 |
| Montelukast Sodium | Montelukast Sodium | 91 | 17 |
| Alendronate Sodium | Alendronate Sodium | 87 | 17 |
| Azithromycin | Azithromycin | 85 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 18 |
| Lisinopril | Lisinopril | 79 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 20 |
| Trulicity | Dulaglutide | 77 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 14 |
| Sertraline Hcl | Sertraline Hcl | 71 | 12 |
| Allopurinol | Allopurinol | 69 | 12 |
| Glimepiride | Glimepiride | 64 | 13 |
| Metformin Hcl | Metformin Hcl | 64 | 22 |
| Farxiga | Dapagliflozin Propanediol | 63 | 11 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 58 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 13 |
| Famotidine | Famotidine | 58 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 18 |
| Tramadol Hcl | Tramadol Hcl | 56 | 11 |
| Finasteride | Finasteride | 55 | suppressed |
| Prednisone | Prednisone | 55 | 35 |
| Valsartan | Valsartan | 54 | suppressed |
| Gemtesa | Vibegron | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | suppressed |
| Mupirocin | Mupirocin | 50 | 25 |
| Sucralfate | Sucralfate | 50 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Eliquis | Apixaban | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 19 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Ozempic | Semaglutide | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Calcium Acetate | Calcium Acetate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Sulindac | Sulindac | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.24 · 24 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CREON, FARXIGA, FUROSCIX, Fabhalta, Fluad, Flucelvax, GEMTESA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, LINZESS, NURTEC ODT, RAYALDEE, TAVNEOS, VRAYLAR, XYOSTED, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error